Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 145

1.

Does Cannabidiol Protect Against Adverse Psychological Effects of THC?

Niesink RJ, van Laar MW.

Front Psychiatry. 2013 Oct 16;4:130. doi: 10.3389/fpsyt.2013.00130. Review.

2.

Sub-chronic impact of cannabinoids in street cannabis on cognition, psychotic-like symptoms and psychological well-being.

Morgan CJ, Gardener C, Schafer G, Swan S, Demarchi C, Freeman TP, Warrington P, Rupasinghe I, Ramoutar A, Tan N, Wingham G, Lewis S, Curran HV.

Psychol Med. 2012 Feb;42(2):391-400. doi: 10.1017/S0033291711001322. Epub 2011 Jul 29.

PMID:
21798112
3.

Just say 'know': how do cannabinoid concentrations influence users' estimates of cannabis potency and the amount they roll in joints?

Freeman TP, Morgan CJ, Hindocha C, Schafer G, Das RK, Curran HV.

Addiction. 2014 Oct;109(10):1686-94. doi: 10.1111/add.12634. Epub 2014 Jul 16.

PMID:
24894801
4.

Clinical and Preclinical Evidence for Functional Interactions of Cannabidiol and Δ9-Tetrahydrocannabinol.

Boggs DL, Nguyen JD, Morgenson D, Taffe MA, Ranganathan M.

Neuropsychopharmacology. 2018 Jan;43(1):142-154. doi: 10.1038/npp.2017.209. Epub 2017 Sep 6. Review.

PMID:
28875990
5.

Does Cannabis Composition Matter? Differential Effects of Delta-9-tetrahydrocannabinol and Cannabidiol on Human Cognition.

Colizzi M, Bhattacharyya S.

Curr Addict Rep. 2017;4(2):62-74. doi: 10.1007/s40429-017-0142-2. Epub 2017 Apr 29. Review.

6.

Analysis of cannabis seizures in NSW, Australia: cannabis potency and cannabinoid profile.

Swift W, Wong A, Li KM, Arnold JC, McGregor IS.

PLoS One. 2013 Jul 24;8(7):e70052. doi: 10.1371/journal.pone.0070052. Print 2013.

7.
8.

Cannabidiol inhibits THC-elicited paranoid symptoms and hippocampal-dependent memory impairment.

Englund A, Morrison PD, Nottage J, Hague D, Kane F, Bonaccorso S, Stone JM, Reichenberg A, Brenneisen R, Holt D, Feilding A, Walker L, Murray RM, Kapur S.

J Psychopharmacol. 2013 Jan;27(1):19-27. doi: 10.1177/0269881112460109. Epub 2012 Oct 5.

PMID:
23042808
9.

The relationship between cannabidiol and psychosis: A review.

Silva TB, Balbino CQ, Weiber AF.

Ann Clin Psychiatry. 2015 May;27(2):134-41. Review.

PMID:
25954940
10.

Cannabidiol attenuates deficits of visuospatial associative memory induced by Δ(9) tetrahydrocannabinol.

Wright MJ Jr, Vandewater SA, Taffe MA.

Br J Pharmacol. 2013 Dec;170(7):1365-73. doi: 10.1111/bph.12199.

11.

Diminished gray matter in the hippocampus of cannabis users: possible protective effects of cannabidiol.

Demirakca T, Sartorius A, Ende G, Meyer N, Welzel H, Skopp G, Mann K, Hermann D.

Drug Alcohol Depend. 2011 Apr 1;114(2-3):242-5. doi: 10.1016/j.drugalcdep.2010.09.020. Epub 2010 Nov 2.

PMID:
21050680
12.

Simultaneous and sensitive analysis of THC, 11-OH-THC, THC-COOH, CBD, and CBN by GC-MS in plasma after oral application of small doses of THC and cannabis extract.

Nadulski T, Sporkert F, Schnelle M, Stadelmann AM, Roser P, Schefter T, Pragst F.

J Anal Toxicol. 2005 Nov-Dec;29(8):782-9.

PMID:
16356335
13.

Potency trends of Δ9-tetrahydrocannabinol, cannabidiol and cannabinol in cannabis in the Netherlands: 2005-15.

Niesink RJ, Rigter S, Koeter MW, Brunt TM.

Addiction. 2015 Dec;110(12):1941-50. doi: 10.1111/add.13082. Epub 2015 Sep 18.

PMID:
26234170
14.

Brain Imaging Studies on the Cognitive, Pharmacological and Neurobiological Effects of Cannabis in Humans: Evidence from Studies of Adult Users.

Weinstein A, Livny A, Weizman A.

Curr Pharm Des. 2016;22(42):6366-6379. doi: 10.2174/1381612822666160822151323. Review.

PMID:
27549374
15.

Chronic Adolescent Δ9-Tetrahydrocannabinol Treatment of Male Mice Leads to Long-Term Cognitive and Behavioral Dysfunction, Which Are Prevented by Concurrent Cannabidiol Treatment.

Murphy M, Mills S, Winstone J, Leishman E, Wager-Miller J, Bradshaw H, Mackie K.

Cannabis Cannabinoid Res. 2017 Sep 1;2(1):235-246. doi: 10.1089/can.2017.0034. eCollection 2017.

16.

Cannabidiol, a Major Non-Psychotropic Cannabis Constituent Enhances Fracture Healing and Stimulates Lysyl Hydroxylase Activity in Osteoblasts.

Kogan NM, Melamed E, Wasserman E, Raphael B, Breuer A, Stok KS, Sondergaard R, Escudero AV, Baraghithy S, Attar-Namdar M, Friedlander-Barenboim S, Mathavan N, Isaksson H, Mechoulam R, Müller R, Bajayo A, Gabet Y, Bab I.

J Bone Miner Res. 2015 Oct;30(10):1905-13. doi: 10.1002/jbmr.2513. Epub 2015 May 10.

17.

Potency of delta 9-THC and other cannabinoids in cannabis in England in 2005: implications for psychoactivity and pharmacology.

Potter DJ, Clark P, Brown MB.

J Forensic Sci. 2008 Jan;53(1):90-4. doi: 10.1111/j.1556-4029.2007.00603.x.

PMID:
18279244
18.

Cannabidiol fails to reverse hypothermia or locomotor suppression induced by Δ(9) -tetrahydrocannabinol in Sprague-Dawley rats.

Taffe MA, Creehan KM, Vandewater SA.

Br J Pharmacol. 2015 Apr;172(7):1783-91. doi: 10.1111/bph.13024. Epub 2015 Jan 23.

19.

Therapeutic Effects of Prolonged Cannabidiol Treatment on Psychological Symptoms and Cognitive Function in Regular Cannabis Users: A Pragmatic Open-Label Clinical Trial.

Solowij N, Broyd SJ, Beale C, Prick JA, Greenwood LM, van Hell H, Suo C, Galettis P, Pai N, Fu S, Croft RJ, Martin JH, Yücel M.

Cannabis Cannabinoid Res. 2018 Mar 1;3(1):21-34. doi: 10.1089/can.2017.0043. eCollection 2018.

20.

A behavioural comparison of acute and chronic Delta9-tetrahydrocannabinol and cannabidiol in C57BL/6JArc mice.

Long LE, Chesworth R, Huang XF, McGregor IS, Arnold JC, Karl T.

Int J Neuropsychopharmacol. 2010 Aug;13(7):861-76. doi: 10.1017/S1461145709990605. Epub 2009 Sep 29.

PMID:
19785914

Supplemental Content

Support Center